The current study met its primary and secondary endpoints, demonstrating that peoplewith T1DM treated with insulin pump therapy could safely improve the percentage oftime spent within the target range without an increase in hypoglycemia orsignificant hyperglycemia, if they use the TBR and EB features to adjust insulinaccording to their requirements during the month of Ramadan. The gene discussed is INS; the disease is Hypoglycemia.